The BPI expresses its support for the European Commission's proposed European Innovation Act. The Draghi report highlighted health innovation as a key element of Europe’s competitiveness, a perspective echoed by Commission President Ursula von der Leyen in her State of the Union address, where she underscored the Union’s readiness to assume global health leadership. To realise this shared vision, pharmaceutical innovation should be recognised as a strategic investment rather than a cost factor, and should be underpinned by updated EU reporting standards and more effective impact indicators.
